Doug’s FlareTx Characteristics: A player coach laser focused on being part of a high performing team transforming world-class science into innovative medicines for patients in need.

Doug is a proven leader and company operator with over two decades of company building and drug development expertise.

Most recently, Doug was the Chief Executive Officer of a publicly traded autoimmune and oncology company. Prior to joining Aclaris Therapeutics, he was Executive Vice President of Research and Development at Arena Pharmaceuticals, where he oversaw all research and development activities until its acquisition by Pfizer. Dr. Manion joined Arena after serving as Chief Executive Officer of Kleo Pharmaceuticals, a private immuno-oncology company, from 2017 until its acquisition by Biohaven Holdings in January 2021. Previously Dr. Manion spent eleven years at BMS, holding various leadership roles in global clinical research, clinical development, pharmacovigilance and biostatistics, across various therapeutic areas, including virology, immunology, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis.

He is Board Certified in Internal Medicine and completed an Infectious Diseases Fellowship at the University of Ottawa in Ontario, Canada followed by post-doctoral training at Massachusetts General Hospital and Harvard Medical School.

Outside of work, Doug enjoys hiking, golf, tennis, opera, cooking and travel.